> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Taps Murphy to Head Generic Drugs Office
- URL: https://www.fdaweb.com/fda-taps-murphy-to-head-generic-drugs-office/
- Published: 2023-06-08T12:00:00.000Z
- Updated: 2026-09-14T18:37:25.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5154651

FDA has selected CDER Office of Generic Drugs (OGD) safety and clinical evaluation acting director **Iilun Murphy** to serve as the next OGD director, replacing **Sally Choe**, who left the agency eight months ago to pursue opportunities outside the agency. CDER Office of Lifecycle Drug Products director **Susan Rosencrance**, who has served as acting OGD director since October, will assist with the transition period as the acting principal deputy director for OGD before returning to her previous role at the end of August, according to an agency email announcing the change.

Murphy began her FDA career in 2007 as a medical officer in the Division of Gastroenterology Products in the Office of New Drugs. She is a board-certified pediatrician and an assistant clinical professor of pediatrics at the George Washington University School of Medicine. Murphy has a bachelor’s degree from Cornell University and a medical degree from Stanford University.